US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NeOnc Technologies Holdings

4.69

+0.08501.85%

Pre-market: 4.750.0600+1.28%08:16 EDT

Volume:100.68K

Turnover:467.37K

Market Cap:122.00M

PE:-2.20

High:4.75

Open:4.57

Low:4.51

Close:4.61

52wk High:12.99

52wk Low:3.01

Shares:26.01M

Float Shares:9.16M

Volume Ratio:0.67

T/O Rate:1.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1361

EPS(LYR):-3.2036

ROE:--

ROA:-634.99%

PB:-5.63

PE(LYR):-1.46

Loading ...

Overview Company News Filings

NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger

NeOnc’s Clinical Story Is Now the Main Event

NeOnc Technologies Amends 8-K to Name Nasim Shomali to Audit Committee

Calendar of U.S. Earnings Expected in the Week Ahead

Neonc Technologies CEO Thomas C. Chen Acquires $70,010 of Common Shares Via IRA

NeOnc Technologies Hosts Annual Shareholder Meeting Via Webcast

Calendar of U.S. Earnings Expected in the Week Ahead

NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t

Neonc Technologies CEO Amir F Heshmatpour Acquires USD 58,521 of Common Shares

NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results

NeOnc Technologies Releases Transcript of Investor Call on Neo100-01 Phase 2a Trial Results in Recurrent IDH1-Mutant High-Grade Glioma

The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Neonc Technologies - no Major Toxicities Reported in Phase 2a Neo100 Cohort

THOMSON REUTERS

Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

NeOnc Technologies Says Phase 2a Trial of Intranasal NEO100 Met Progression-Free Survival Primary Endpoint

MT Newswires Live

NeOnc Technologies Says Brain Tumor Drug Trial Met Primary Endpoint

NeOnc Rises as Experimental Brain Cancer Therapy Meets Main Study Goal

NeOnc Reports Phase 2a Neo100 Trial Hits Six-Month PFS Endpoint in Recurrent IDH1-Mutant High-Grade Glioma

Neonc Technologies - no Major Toxicities Reported; Adverse Events Predominantly Low-Grade

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/NTHI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NTHI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","market":"US","secType":"STK","nameCN":"NeOnc Technologies Holdings","latestPrice":4.69,"timestamp":1787947200000,"preClose":4.605,"halted":0,"volume":100679,"hourTrading":{"tag":"盘前","latestPrice":4.75,"preClose":4.69,"latestTime":"08:16 EDT","volume":173,"amount":825.280065,"timestamp":1788178582255,"change":0.06,"changeRate":0.012793,"amplitude":0.074627},"delay":0,"changeRate":0.018458197611292065,"floatShares":9155900,"shares":26013100,"eps":-2.136127,"marketStatus":"Pre-Mkt","change":0.085,"latestTime":"08-31 08:46:54 EDT","open":4.57,"high":4.75,"low":4.51,"amount":467369.1743806,"amplitude":0.052117,"askPrice":6.3,"askSize":500,"bidPrice":4.75,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.136127,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788183000000},"marketStatusCode":1,"adr":0,"listingDate":1711512000000,"exchange":"NASDAQ","adjPreClose":4.69,"preHourTrading":{"tag":"盘前","latestPrice":4.75,"preClose":4.69,"latestTime":"08:16 EDT","volume":173,"amount":825.280065,"timestamp":1788178582255,"change":0.06,"changeRate":0.012793,"amplitude":0.074627},"postHourTrading":{"tag":"盘后","latestPrice":4.69,"preClose":4.69,"latestTime":"19:30 EDT","volume":173,"amount":799.515,"timestamp":1787959806585,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6656973365224226},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","floatShares":9155900,"roa":"-634.99%","roe":"--","lyrEps":-3.203615,"volumeRatio":0.6656973365224226,"shares":26013100,"dividePrice":0,"high":4.75,"amplitude":0.052117,"preClose":4.605,"low":4.51,"week52Low":3.005,"pbRate":"-5.63","psRate":"3050.80","week52High":12.99,"institutionHeld":0,"latestPrice":4.69,"committee":-0.666667,"eps":-2.136127,"divideRate":0,"volume":100679,"delay":0,"ttmEps":-2.136127,"open":4.57,"prevYearClose":8.27,"prevWeekClose":4.69,"prevMonthClose":3.49,"prevQuarterClose":4.53,"fiveDayClose":4.675,"twentyDayClose":3.49,"sixtyDayClose":4.35},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NTHI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-10","symbol":"NTHI","fiscalQuarterEnding":"2026/06","expectedEps":-0.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786334400000,"reportTimeType":"pre","actualEps":-0.58},{"market":"US","date":"2026-05-15","symbol":"NTHI","fiscalQuarterEnding":"2026/03","expectedEps":-0.3,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.38},{"market":"US","date":"2026-03-31","symbol":"NTHI","fiscalQuarterEnding":"2025/12","expectedEps":-0.37,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"pre","actualEps":-0.72},{"market":"US","date":"2025-11-14","symbol":"NTHI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-18","symbol":"NTHI","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1755489600000,"reportTimeType":"","actualEps":-0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NTHI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NTHI\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1779249600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NTHI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NTHI","date":"2026-08-28","current":-2.195562,"percent":0.719888,"low":-26.074295,"twenty":-4.273416,"median":-3.115982,"eighty":-2.26624,"high":-1.357276,"avg":-3.994517,"sd":3.259749,"marketCap":114465665},"quantilePoints":[{"date":"2024-03-28","current":-18.899455,"twenty":-18.899455,"median":-18.899455,"eighty":-18.899455,"marketCap":282000000},{"date":"2025-03-28","current":-18.905834,"twenty":-19.009816,"median":-18.905834,"eighty":-18.902007,"marketCap":224950380},{"date":"2025-04-04","current":-15.093157,"twenty":-20.260752,"median":-18.902645,"eighty":-16.151884,"marketCap":179585386},{"date":"2025-04-11","current":-14.179375,"twenty":-19.504518,"median":-17.739974,"eighty":-15.124667,"marketCap":168712785},{"date":"2025-04-17","current":-11.028403,"twenty":-19.044476,"median":-15.392499,"eighty":-12.855967,"marketCap":131221055},{"date":"2025-04-25","current":-9.437162,"twenty":-18.904558,"median":-14.667776,"eighty":-10.965384,"marketCap":112287731},{"date":"2025-05-02","current":-8.444606,"twenty":-18.667559,"median":-12.525115,"eighty":-9.437162,"marketCap":100477836},{"date":"2025-05-09","current":-10.398208,"twenty":-17.342951,"median":-11.028403,"eighty":-9.33318,"marketCap":123722709},{"date":"2025-05-16","current":-2.933338,"twenty":-15.682389,"median":-10.398208,"eighty":-8.444606,"marketCap":137753858},{"date":"2025-05-23","current":-2.969802,"twenty":-15.348385,"median":-9.44504,"eighty":-3.015179,"marketCap":139466268},{"date":"2025-05-30","current":-2.99006,"twenty":-15.171931,"median":-9.437162,"eighty":-2.969802,"marketCap":140417606},{"date":"2025-06-06","current":-3.034627,"twenty":-15.093157,"median":-9.311123,"eighty":-2.969802,"marketCap":142510552},{"date":"2025-06-13","current":-2.593006,"twenty":-14.242395,"median":-8.476116,"eighty":-2.937389,"marketCap":121771366},{"date":"2025-06-20","current":-1.928548,"twenty":-14.191979,"median":-7.853798,"eighty":-2.929004,"marketCap":90567453},{"date":"2025-06-27","current":-1.616577,"twenty":-12.855967,"median":-3.034627,"eighty":-2.802066,"marketCap":75916836},{"date":"2025-07-03","current":-2.362066,"twenty":-12.222621,"median":-3.010317,"eighty":-2.532985,"marketCap":110926104},{"date":"2025-07-11","current":-1.977167,"twenty":-11.425425,"median":-2.998163,"eighty":-2.362066,"marketCap":92850666},{"date":"2025-07-18","current":-1.786743,"twenty":-11.028403,"median":-2.99006,"eighty":-2.222692,"marketCap":83908082},{"date":"2025-07-25","current":-1.904238,"twenty":-10.981139,"median":-2.959854,"eighty":-1.949616,"marketCap":89425847},{"date":"2025-08-01","current":-1.98527,"twenty":-10.618776,"median":-2.937389,"eighty":-1.970684,"marketCap":93231202},{"date":"2025-08-08","current":-1.944754,"twenty":-10.133526,"median":-2.931642,"eighty":-1.939892,"marketCap":91328524},{"date":"2025-08-15","current":-2.102765,"twenty":-9.654579,"median":-2.909028,"eighty":-1.943134,"marketCap":98748967},{"date":"2025-08-22","current":-2.604584,"twenty":-9.443464,"median":-2.799635,"eighty":-1.954478,"marketCap":110548110},{"date":"2025-08-29","current":-3.15078,"twenty":-9.437162,"median":-2.795584,"eighty":-1.970684,"marketCap":133730643},{"date":"2025-09-05","current":-3.371966,"twenty":-9.437162,"median":-2.876616,"eighty":-1.980408,"marketCap":143118611},{"date":"2025-09-12","current":-4.405675,"twenty":-9.43086,"median":-2.918386,"eighty":-1.98527,"marketCap":186992991},{"date":"2025-09-19","current":-5.457439,"twenty":-9.377293,"median":-2.933338,"eighty":-1.993373,"marketCap":231633736},{"date":"2025-09-26","current":-4.681029,"twenty":-9.292217,"median":-2.939656,"eighty":-2.005528,"marketCap":198680053},{"date":"2025-10-03","current":-5.141458,"twenty":-8.961365,"median":-2.969802,"eighty":-2.008769,"marketCap":218222354},{"date":"2025-10-10","current":-5.407785,"twenty":-8.482417,"median":-2.99006,"eighty":-2.016872,"marketCap":229526233},{"date":"2025-10-17","current":-4.730683,"twenty":-8.444606,"median":-3.002214,"eighty":-2.039561,"marketCap":200787556},{"date":"2025-10-24","current":-3.769199,"twenty":-7.97196,"median":-3.022472,"eighty":-2.067922,"marketCap":159978635},{"date":"2025-10-31","current":-4.590749,"twenty":-7.105442,"median":-3.15078,"eighty":-2.071973,"marketCap":194848230},{"date":"2025-11-07","current":-4.446301,"twenty":-6.304447,"median":-3.298614,"eighty":-2.085748,"marketCap":188717312},{"date":"2025-11-14","current":-4.053582,"twenty":-5.457439,"median":-3.638293,"eighty":-2.120592,"marketCap":172048879},{"date":"2025-11-21","current":-2.32457,"twenty":-5.457439,"median":-3.482559,"eighty":-2.150574,"marketCap":113613569},{"date":"2025-11-28","current":-3.566132,"twenty":-5.449314,"median":-3.447134,"eighty":-2.162729,"marketCap":174295011},{"date":"2025-12-05","current":-3.725512,"twenty":-5.41591,"median":-3.522302,"eighty":-2.193521,"marketCap":182084733},{"date":"2025-12-12","current":-3.733481,"twenty":-5.411396,"median":-3.568124,"eighty":-2.214589,"marketCap":182474219},{"date":"2025-12-19","current":-2.797122,"twenty":-5.405979,"median":-3.570116,"eighty":-2.278603,"marketCap":136709607},{"date":"2025-12-26","current":-3.327062,"twenty":-5.398757,"median":-3.566132,"eighty":-2.301292,"marketCap":162610430},{"date":"2026-01-02","current":-3.295186,"twenty":-5.391535,"median":-3.474488,"eighty":-2.319914,"marketCap":161052485},{"date":"2026-01-09","current":-3.916768,"twenty":-5.368062,"median":-3.548202,"eighty":-2.33285,"marketCap":191432398},{"date":"2026-01-16","current":-3.466519,"twenty":-5.344589,"median":-3.566132,"eighty":-2.344813,"marketCap":169426436},{"date":"2026-01-23","current":-3.486442,"twenty":-5.296741,"median":-3.53824,"eighty":-2.348861,"marketCap":170400151},{"date":"2026-01-30","current":-3.486442,"twenty":-5.229933,"median":-3.552186,"eighty":-2.357204,"marketCap":170400151},{"date":"2026-02-06","current":-3.681683,"twenty":-5.174862,"median":-3.566132,"eighty":-2.362066,"marketCap":179942559},{"date":"2026-02-13","current":-4.169784,"twenty":-5.146875,"median":-3.570116,"eighty":-2.389761,"marketCap":203798580},{"date":"2026-02-20","current":-3.426674,"twenty":-5.12611,"median":-3.574101,"eighty":-2.410019,"marketCap":167479005},{"date":"2026-02-27","current":-4.020365,"twenty":-5.049824,"median":-3.613946,"eighty":-2.417236,"marketCap":196495717},{"date":"2026-03-06","current":-3.835101,"twenty":-4.966315,"median":-3.638073,"eighty":-2.428412,"marketCap":187440892},{"date":"2026-03-13","current":-3.660224,"twenty":-4.933814,"median":-3.653791,"eighty":-2.438178,"marketCap":178893747},{"date":"2026-03-20","current":-3.253532,"twenty":-4.851659,"median":-3.642057,"eighty":-2.502974,"marketCap":159016664},{"date":"2026-03-27","current":-2.981402,"twenty":-4.767698,"median":-3.621915,"eighty":-2.597637,"marketCap":145716276},{"date":"2026-04-02","current":-1.961459,"twenty":-4.735197,"median":-3.603287,"eighty":-2.595322,"marketCap":121897269},{"date":"2026-04-10","current":-1.961307,"twenty":-4.734294,"median":-3.574101,"eighty":-2.414974,"marketCap":121887825},{"date":"2026-04-17","current":-2.012281,"twenty":-4.720752,"median":-3.566132,"eighty":-2.352342,"marketCap":125055639},{"date":"2026-04-24","current":-1.920085,"twenty":-4.679223,"median":-3.562148,"eighty":-2.305948,"marketCap":119325998},{"date":"2026-05-01","current":-1.771769,"twenty":-4.657556,"median":-3.53824,"eighty":-2.205893,"marketCap":110108750},{"date":"2026-05-08","current":-2.630543,"twenty":-4.597971,"median":-3.502161,"eighty":-2.162729,"marketCap":163478290},{"date":"2026-05-15","current":-2.213061,"twenty":-4.588041,"median":-3.478473,"eighty":-2.19289,"marketCap":137533354},{"date":"2026-05-22","current":-3.511755,"twenty":-4.577207,"median":-3.486442,"eighty":-2.19724,"marketCap":135694649},{"date":"2026-05-29","current":-3.138303,"twenty":-4.577207,"median":-3.483777,"eighty":-2.19881,"marketCap":121264435},{"date":"2026-06-05","current":-2.990888,"twenty":-4.568179,"median":-3.474488,"eighty":-2.200003,"marketCap":115568297},{"date":"2026-06-12","current":-2.948302,"twenty":-4.559151,"median":-3.434643,"eighty":-2.209008,"marketCap":113922747},{"date":"2026-06-18","current":-3.151407,"twenty":-4.512205,"median":-3.406752,"eighty":-2.21225,"marketCap":121770758},{"date":"2026-06-26","current":-2.954853,"twenty":-4.486024,"median":-3.393823,"eighty":-2.226031,"marketCap":114175908},{"date":"2026-07-02","current":-2.922095,"twenty":-4.474288,"median":-3.367616,"eighty":-2.229383,"marketCap":112910100},{"date":"2026-07-10","current":-3.013469,"twenty":-4.460746,"median":-3.339093,"eighty":-2.231778,"marketCap":116440808},{"date":"2026-07-17","current":-2.181241,"twenty":-4.449912,"median":-3.327062,"eighty":-2.231778,"marketCap":84283436},{"date":"2026-07-24","current":-2.436279,"twenty":-4.432759,"median":-3.283232,"eighty":-2.231778,"marketCap":94138114},{"date":"2026-07-31","current":-2.342317,"twenty":-4.416509,"median":-3.25181,"eighty":-2.244708,"marketCap":90507443},{"date":"2026-08-07","current":-2.349029,"twenty":-4.389966,"median":-3.211511,"eighty":-2.26624,"marketCap":90766777},{"date":"2026-08-14","current":-1.763689,"twenty":-4.333179,"median":-3.181853,"eighty":-2.231004,"marketCap":83246101},{"date":"2026-08-21","current":-2.401422,"twenty":-4.279913,"median":-3.15078,"eighty":-2.244708,"marketCap":113347108},{"date":"2026-08-28","current":-2.42512,"twenty":-4.273416,"median":-3.115982,"eighty":-2.26624,"marketCap":114465665}],"updateTime":1788160562475},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NTHI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662366091","title":"NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger","url":"https://stock-news.laohu8.com/highlight/detail?id=2662366091","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662366091?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:07","pubTimestamp":1787926020,"startTime":"0","endTime":"0","summary":"to “What would it take to get NEO100 to a potential approval?”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/28/3352739/0/en/neonc-s-phase-2a-success-could-set-the-stage-for-something-much-bigger.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662175127","title":"NeOnc’s Clinical Story Is Now the Main Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2662175127","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662175127?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:39","pubTimestamp":1787751540,"startTime":"0","endTime":"0","summary":"DENVER, Aug.  26, 2026  -- NeOnc Technologies Holdings  has reached a point where the market conversation can move toward a much more consequential question: What happens if NEO100’s clinical results translate into a viable regulatory pathway for a difficult-to-treat form of brain cancer?","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351481/0/en/neonc-s-clinical-story-is-now-the-main-event.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","BK4585","BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661929902","title":"NeOnc Technologies Amends 8-K to Name Nasim Shomali to Audit Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2661929902","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661929902?lang=en_us&edition=fundamental","pubTime":"2026-08-22 02:59","pubTimestamp":1787338770,"startTime":"0","endTime":"0","summary":"NeOnc Technologies amends 8-K to name Nasim Shomali to audit committeeNeOnc Technologies filed an amended 8-K to update board committee assignments omitted from its July 2, 2026 report.Nasim Shomali w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL4NLHMr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661261695","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2661261695","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661261695?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:00","pubTimestamp":1787306400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. ·PicS N.V. Class A                               2Q       .40       AMC. ·Bank Nova Scot.                                  3Q      1.49   6:00 AM. ·Everpure Inc A                                     2Q       .58   4:05 PM. ·JM Smucker Co.                                   1Q      2.22   7:00 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNS","BOX","BILI","A","GAP","DKS","IREN","BURL","BEKE","CRWD","AFRM","HPQ","BZ","MBUU","HQY","INTU","HRL","NSSC","AVNW","CMBT","CDLR","JKS","NTHI","MRVL","ADSK","DCI","NTNX","CM","CRM","DY","KSS","DG","ESTC","MZTI","MCFT","HEI","BBY","LI","BBW","HEI.A","BBAR","DLTR","JOYY","VIPS","NCNO","CSIQ","BJ","BMO","LTRX","BBWI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661255174","title":"Neonc Technologies CEO Thomas C. Chen Acquires $70,010 of Common Shares Via IRA","url":"https://stock-news.laohu8.com/highlight/detail?id=2661255174","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661255174?lang=en_us&edition=fundamental","pubTime":"2026-08-21 09:16","pubTimestamp":1787274992,"startTime":"0","endTime":"0","summary":"Neonc Technologies CEO Thomas C. Chen acquires $70,010 of common shares via IRANeonc Technologies CEO Thomas C. Chen reported an indirect purchase of 12,757 common shares at a weighted average price o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL7CMxLX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Neonc Technologies CEO Thomas C. Chen Acquires $70,010 of Common Shares Via IRA","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660100282","title":"NeOnc Technologies Hosts Annual Shareholder Meeting Via Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2660100282","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660100282?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:01","pubTimestamp":1787230877,"startTime":"0","endTime":"0","summary":"NeOnc Technologies hosts annual shareholder meeting via webcastNeOnc Technologies Holdings held its annual shareholder meeting on Aug. 14, 2026.Shareholders elected Victoria Medvec and Steven Giannott","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL2H01Kq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660411424","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2660411424","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660411424?lang=en_us&edition=fundamental","pubTime":"2026-08-19 18:00","pubTimestamp":1787133600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. ·Estee Lauder Co.                                  4Q       .32   6:00 AM. ·FLEX LNG Ltd                                    2Q       .62   1:00 AM. ·Adv Auto Parts                                   2Q       .81   6:30 AM. ·Atour Life ADR                                  2Q       .58   6:00 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOX","PRLD","FLO","KC","BEEM","HEI.A","ALVO","FLUX","FLNG","NMTC","PICS","NCNO","LYTS","BABA","COTY","DKS","ROST","OSIS","ANF","AAP","BJ","FUTU","DOMO","HEI","JOYY","ATHM","NTHI","BMO","ADI","NTES","BNS","VIPS","INTU","LOW","BILL","BZ","NMM","EL","MRKR","BMA","PDD","GGAL","BEKE","SCSC","DE","NDSN","MZTI","CDLR","ATAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660149394","title":"NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t","url":"https://stock-news.laohu8.com/highlight/detail?id=2660149394","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660149394?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:18","pubTimestamp":1787062680,"startTime":"0","endTime":"0","summary":"NeOnc Insider Open Market Buying may be the Signal Worth WatchingDENVER, Aug.  18, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) --NeOnc Technologies Holdings (NASDAQ: NTHI) has just added another pote","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/18/3347038/0/en/neonc-technologies-talk-is-cheap-insider-buying-isn-t.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660343053","title":"Neonc Technologies CEO Amir F Heshmatpour Acquires USD 58,521 of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2660343053","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660343053?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:50","pubTimestamp":1787007027,"startTime":"0","endTime":"0","summary":"Neonc Technologies CEO Amir F Heshmatpour acquires USD 58,521 of common sharesNeonc Technologies: CEO, President Amir F. Heshmatpour disclosed open-market purchases totaling 15,000 common shares.Direc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL268MWD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Neonc Technologies CEO Amir F Heshmatpour Acquires USD 58,521 of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660589438","title":"NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2660589438","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660589438?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:45","pubTimestamp":1786970700,"startTime":"0","endTime":"0","summary":"Every meaningful milestone can reduce some of that uncertainty, which is why successful Phase 2a data can be transformative for a biotech company even before the drug generates commercial revenue. In NTHI’s case, the reported 48.9% six-month PFS result substantially exceeded the company's 20% historical benchmark, while the company also reported median overall survival of approximately 26 months and no major toxicities. The next question is no longer simply whether NEO100 can produce a clinical signal and becomes How far can NeOnc take that signal?That is where capital becomes critical. Clinical Success Creates a New Kind of Financing Opportunity A promising Phase 2a result can potentially change the economics of raising money because management is no longer asking investors to finance only a scientific hypothesis. The company can point to an actual human clinical outcome. That doesn't eliminate risk, establish regulatory approval or guarantee that a larger study will reproduce the res","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/17/3346121/0/en/nthi-s-nasdaq-advantage-takes-on-new-meaning-after-its-breakthrough-phase-2a-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659989361","title":"NeOnc Technologies Releases Transcript of Investor Call on Neo100-01 Phase 2a Trial Results in Recurrent IDH1-Mutant High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2659989361","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659989361?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:22","pubTimestamp":1786656134,"startTime":"0","endTime":"0","summary":"NeOnc Technologies releases transcript of investor call on NEO100-01 Phase 2a trial results in recurrent IDH1-mutant high-grade gliomaNeonc Technologies hosted an investor call on Aug. 12, 2026 to dis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL7HkSQ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659164587","title":"The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2659164587","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659164587?lang=en_us&edition=fundamental","pubTime":"2026-08-14 02:31","pubTimestamp":1786645860,"startTime":"0","endTime":"0","summary":"Stunning Brain-Cancer Data Are Putting NeOnc’s Nose-to-Brain Delivery Platform, and Its Broader Potential, Front and CenterDENVER, Aug.  13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings’ (NASD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344837/0/en/the-nose-knows-why-neonc-s-patent-portfolio-could-make-nthi-more-than-a-one-drug-biotech.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","XBI","BK4581","BK4007","BK4588","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659092299","title":"U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2659092299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659092299?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:17","pubTimestamp":1786551433,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sutro Biopharma, HumacyteAugust 12 (Reuters)-Wall Street's main indexes rose on Wednesday, with the Nasdaq outperforming peers as upbeat earnings from AI infrastructure fi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL6N4490YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","SVV","SMMT","TAN","SLN","SMCI","NBIS","O","ANNX","SMCL","NCMI","SLXN","DPRE","LAZR","TECH","CHTR","HUMA","NTHI","NBIX","UAMY","UFO","CAVA","LQDA","OFAL","ALT","TSHA","EAT","PFGC","SMWB","HRB","CIEN","GAP","CRWV","EROC","DFTX","TRMB","NBIZ","LUMA","FSLR","OPLN","TPL","CORD","ABSI","WXM","STRO","SLNCF","LOCL","LITE","BETA","EGGY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908157","title":"Neonc Technologies - no Major Toxicities Reported in Phase 2a Neo100 Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908157?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:38","pubTimestamp":1786541937,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN44914H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658590389","title":"Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2658590389","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658590389?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:38","pubTimestamp":1786541880,"startTime":"0","endTime":"0","summary":"DALLAS, Aug.  12, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has delivered the kind of clinical update that can change the conversation around a small biotechnology company: i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343786/0/en/targeting-the-mutant-nthi-s-neo100-data-could-open-a-new-front-in-the-fight-against-brain-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658977252","title":"NeOnc Technologies Says Phase 2a Trial of Intranasal NEO100 Met Progression-Free Survival Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2658977252","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658977252?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:43","pubTimestamp":1786538586,"startTime":"0","endTime":"0","summary":"NeOnc Technologies  said Wednesday the phase 2a portion of its trial of intranasal NEO100 in recurrent or progressive IDH1-mutant high-grade glioma met its primary endpoint with a six-month progression-free survival of 48.9%.The trial further demonstrated a median overall survival of 26.09 months, with 12 deaths among 24 patients. Overall survival was 86.7% at six months, 60.9% at 12 months and 54.1% at 24 months, according to the company.Looking ahead, NeOnc Technologies said it will request a type B meeting with the US Food and Drug Administration to align on a registrational development path for NEO100 in recurrent IDH1-mutant high-grade glioma.Shares of the company were up over 1% in Wednesday premarket activity.Price: 4.37, Change: +0.02, Percent Change: +1.15","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658977122","title":"NeOnc Technologies Says Brain Tumor Drug Trial Met Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2658977122","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658977122?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:35","pubTimestamp":1786538100,"startTime":"0","endTime":"0","summary":"NeOnc Technologies said its recent study of a brain tumor treatment met its primary endpoint.Nearly 49% of patients with recurrent or progressive IDH1-mutant glioma brain tumors had six-month progression-free survival during the study, the biopharmaceutical company said Wednesday.That compared with a 20% benchmark rate set before the trial began.The treatment, known as NEO100, was administered through the nose by patients at home, with no major toxicities reported. Administering the treatment through the nose allows it to pass through the blood-brain barrier, which has been a challenge in treating brain cancer.Median overall survival was 26 months, with 12 deaths among the 24 patients. Overall survival was 87% at six months, 61% at 12 months and 54% at 24 months. Of the original 24 patients, five remain in active treatment.NeOnc's next priority is to engage with the Food and Drug Administration and align on the best path toward a registrational study, Chief Executive Amir Heshmatpour s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658229972","title":"NeOnc Rises as Experimental Brain Cancer Therapy Meets Main Study Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2658229972","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658229972?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:15","pubTimestamp":1786536931,"startTime":"0","endTime":"0","summary":"BUZZ-NeOnc rises as experimental brain cancer therapy meets main study goal** Shares of NeOnc TechnologiesNTHI.Orise 12.4% to $4.89 premarket** The clinical-stage brain cancer drug developer says expe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4N4490WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658196972","title":"NeOnc Reports Phase 2a Neo100 Trial Hits Six-Month PFS Endpoint in Recurrent IDH1-Mutant High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2658196972","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658196972?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:08","pubTimestamp":1786536508,"startTime":"0","endTime":"0","summary":"NeOnc reports Phase 2a NEO100 trial hits six-month PFS endpoint in recurrent IDH1-mutant high-grade gliomaNeOnc reported positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL8pBYcT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","IE00BKPKM429.USD","LU2095319765.USD","SG9999014021.USD","SG9999014039.USD","BK4007","BCDF","SG9999014005.SGD","IE00B64PRP62.GBP","BK4112","SG9999014013.SGD","LU2210150020.SGD","BK4585","BK4588","LU0314104364.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972591","title":"Neonc Technologies - no Major Toxicities Reported; Adverse Events Predominantly Low-Grade","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972591?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2KTJGZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":108,"code":"91000000","status":"200"}]}}